Insufficient Control of Blood Pressure and Incident Diabetes

OBJECTIVE Incidence of type 2 diabetes might be associated with preexisting hypertension. There is no information on whether incident diabetes is predicted by blood pressure control. We evaluated the hazard of diabetes in relation to blood pressure control in treated hypertensive patients. RESEARCH DESIGN AND METHODS Nondiabetic, otherwise healthy, hypertensive patients (N = 1,754, mean ± SD age 52 ± 11 years, 43% women) participated in a network over 3.4 ± 1 years of follow-up. Blood pressure was considered uncontrolled if systolic was ≥140 mmHg and/or diastolic was ≥90 mmHg at the last outpatient visit. Diabetes was defined according to American Diabetes Association guidelines. RESULTS Uncontrolled blood pressure despite antihypertensive treatment was found in 712 patients (41%). At baseline, patients with uncontrolled blood pressure were slightly younger than patients with controlled blood pressure (51 ± 11 vs. 53 ± 12 years, P < 0.001), with no differences in sex distribution, BMI, duration of hypertension, baseline blood pressure, fasting glucose, serum creatinine and potassium, lipid profile, or prevalence of metabolic syndrome. During follow-up, 109 subjects developed diabetes. Incidence of diabetes was significantly higher in patients with uncontrolled (8%) than in those with controlled blood pressure (4%, odds ratio 2.08, P < 0.0001). In Cox regression analysis controlling for baseline systolic blood pressure and BMI, family history of diabetes, and physical activity, uncontrolled blood pressure doubled the risk of incident diabetes (hazard ratio [HR] 2.10, P < 0.001), independently of significant effects of age (HR 1.02 per year, P = 0.03) and baseline fasting glucose (HR 1.10 per mg/dl, P < 0.001). CONCLUSIONS In a large sample of treated nondiabetic hypertensive subjects, uncontrolled blood pressure is associated with twofold increased risk of incident diabetes independently of age, BMI, baseline blood pressure, or fasting glucose.

[1]  C. Dollery,et al.  Glucose Tolerance During Antihypertensive Therapy in Patients with Diabetes Mellitus , 1985, Hypertension.

[2]  Masafumi Matsuda,et al.  beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[3]  Michael M Engelgau,et al.  Elevated blood pressure among U.S. adults with diabetes, 1988-1994. , 2002, American journal of preventive medicine.

[4]  H. Aburatani,et al.  Angiotensin II–Induced Insulin Resistance Is Associated With Enhanced Insulin Signaling , 2002, Hypertension.

[5]  L. Wilhelmsen,et al.  Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up , 2007, Journal of hypertension.

[6]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[7]  O. Arcucci,et al.  Association of suboptimal blood pressure control with body size and metabolic abnormalities , 2007, Journal of hypertension.

[8]  Raffaele Izzo,et al.  The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis , 2005, Journal of hypertension.

[9]  R. Devereux,et al.  Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study , 2007, Journal of Human Hypertension.

[10]  G. Reboldi,et al.  New-onset diabetes, antihypertensive treatment, and outcome. , 2007, Hypertension.

[11]  B. Trimarco,et al.  Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. , 1992, The Journal of clinical investigation.

[12]  G. D. Johnston,et al.  A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM , 1995, Diabetologia.

[13]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[14]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[15]  F. Nieto,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .

[16]  Paul Mitchell,et al.  Retinal Arteriolar Narrowing Predicts Incidence of Diabetes , 2008, Diabetes.

[17]  P. Raskin,et al.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. , 2004, JAMA.

[18]  O. Arcucci,et al.  beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene. , 2005, The pharmacogenomics journal.

[19]  G. Bray,et al.  Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. , 2008, The American journal of clinical nutrition.

[20]  Samia Mora,et al.  Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. , 2007, European heart journal.

[21]  M. Welsh,et al.  Glucose intolerance and reduced islet blood flow in transgenic mice expressing the FRK tyrosine kinase under the control of the rat insulin promoter. , 2007, American journal of physiology. Endocrinology and metabolism.

[22]  M. Fantone,et al.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1997, Diabetes Care.

[23]  S. Hallan,et al.  Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  O. Arcucci,et al.  β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene , 2005, The Pharmacogenomics Journal.

[25]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[26]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[27]  G. Bakris,et al.  Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. , 2006, QJM : monthly journal of the Association of Physicians.